Physician profile
Tammy Guy
NPI 1912261173
$5,110.56
in general payments reported to CMS, 2019-2025
38 companies · $395 in 2025
The $395 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,756 · 2022: $1,692 · 2023: $947 · 2024: $322 · 2025: $395.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,663.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,663.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $1,324.85 | 2021-2023 | Injectafer |
| Amgen INC. | $408.90 | 2021-2025 | Evenity |
| Abbvie INC. | $380.02 | 2021-2023 | |
| Novo Nordisk INC | $288.50 | 2021-2023 | Wegovy |
| Astrazeneca Pharmaceuticals Lp | $221.51 | 2021-2023 | Farxiga |
| Lilly USA, LLC | $218.42 | 2021-2023 | Mounjaro |
| Pfizer INC. | $156.59 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $147.73 | 2021-2023 | Verquvo, Belsomra, Steglatro |
| Abbott Laboratories | $146.95 | 2022-2024 | Freestyle Libre 3 |
| Esperion Therapeutics, INC. | $139.85 | 2021-2022 | |
| Insulet Corporation | $127.13 | 2025 | Omnipod |
| Genentech USA, INC. | $125.00 | 2022 | |
| Phathom Pharmaceuticals, INC. | $125.00 | 2024 | Voquezna |
| Ardelyx, INC. | $125.00 | 2025 | Ibsrela |
| Regeneron Healthcare Solutions, INC. | $125.00 | 2023 | Dupixent |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tammy Guy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.